CARNA BIOSCIENCES

News Release

November 5, 2024
Carna Biosciences, Inc.

Carna Announces International Nonproprietary Name Selection for AS-1763

Carna Biosciences, a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative therapies to treat serious unmet medical needs, today announced that it has received approval of the International Nonproprietary Name (INN) for the company's investigational drug AS-1763 from the World Health Organization (WHO) as below.

Code name	International Nonproprietary Name (INN)
AS-1763	docirbrutinib

INN are assigned by the INN Expert Committee of the WHO to pharmaceutical substances to ensure recognition by a unique name. Going forward, Carna will use the INN for the investigational drug AS-1763 in upcoming publications and public statements.

About AS-1763 (docirbrutinib)

AS-1763 is a highly selective, orally bioavailable, non-covalent inhibitor of both the wild type and mutant BTKs for the treatment of CLL and other B cell malignancies. Covalent BTK inhibitors including ibrutinib are key therapeutic options for patients with B cell malignancies. However, patients are reported to develop resistance during the treatment due to substitution of cysteine residue at 481 position with serine (C481S - 2 -mutation) in BTK, which reduces the efficacy of the covalent BTK inhibitors. In addition, the emergence of other types of resistance mutations to non-covalent BTK inhibitor, recently approved pirtobrutinib, has been reported. AS-1763 potently inhibited both wild type and those mutant BTKs, strongly suggesting that AS-1763 will be a new therapeutic option for treating patients with B cell malignancies both having wild type and resistance mutations in BTK. Carna is advancing development of AS-1763 as a next-generation BTK inhibitor.

The Phase 1b study of AS-1763 is being conducted in the U.S. and dosing in the dose expansion part was initiated in October 2024. Preliminary data from the study which was presented at the European Hematology Association (EHA) 2024 Hybrid Congress in June 2024 by Prof. Nitin Jain, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, who leads the study showed a favorable safety and PK profile as well as promising efficacy in patients with CLL who have been heavily pretreated with systemic therapies including covalent BTK inhibitors and BCL2 inhibitor.

Contact:
Corporate Planning
Carna Biosciences, Inc.
TEL: +81-78-302-7075
https://www.carnabio.com/english/